Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:1
članak: 4 od 16  
Back povratak na rezultate
Vojnosanitetski pregled
2017, vol. 74, br. 8, str. 728-735
jezik rada: engleski
vrsta rada: izvorni naučni članak
objavljeno: 04/08/2017
doi: 10.2298/VSP160322087A
Creative Commons License 4.0
Prognostički značaj metaboličkih tumorskih parametara na inicijalnom FDG-PET/CT kod bolesnika sa izolovanim infradijafragmalnim Hočkinovim limfomom
aGulhane Military Medical Academy and School of Medicine, Department of Nuclear Medicine, Etlik-Ankara, Turkey
bGulhane Military Medical Academy and School of Medicine, Department of Haematology, Etlik-Ankara, Turkey
cTraining and Research Hospital, Ataturk Chest Diseases and Thoracic Surgery, Department of Nuclear Medicine, Kecioren, Ankara, Turkey
dGulhane Military Medical Academy and School of Medicine, Department of Medical Oncology, Etlik-Ankara, Turkey

e-adresa: ealagoz@gata.edu.tr

Sažetak

Uvod/Cilj. Prisustvo izolovanih infradijafragmalnih limfnih čvorova kod Hočkinovog limfoma (HL) nije često i javlja se kod 5–15% svih HL I-II stadijuma. Važni podaci o prognostičkim faktorima i optimalnom lečenju izolovanog infradijafragmalnog HL (IIHL) nisu jasno definisani. Cilj ovog ispitivanja bila je procena prognostičke vrednosti pokazatelja metabolizma tumora na inicijalnom pregledu pomoću 18- fluorodeoksiglukoza-pozitron emisione tomografije /kompjuterizovane tomografije (FDG-PET/CT) preko kvanititativnih PET/CT parametara zajedno sa klasičnim predefinisanim faktorima rizika za bolesnike sa II HL. Metode. U ovu retrospektivnu kohortnu studiju, sprovedenu između 2004. i 2015. godine, bio je uključen 21 bolesnik, kod kojih je za određenjivanje primarnog stadijuma bolesti primenjena FDG-PET/CT. Kvantitativni PET/CT parametri [vrednost maksimalnog standardizovanog preuzimanja (maximum standardized uptake value – SUVmax), prosečna vrednost standardizovanog preuzimanja (mean standardized uptake value – SUVmean), metabolički volumen tumora (metabolic tumor valume – MTV), ukupna glikoliza u lezijama (total lesion glycolysis – TLG)] korišćeni su za procenu preživljavanja bez prisustva bolesti (disease-free survival – DFS) i sveukupnog preživljavanja (overall survival – OS). Rezultati. Izvršena je univarijantna Cox-ova regresiona analiza svih potencijalnih faktora rizika koji imaju uticaj na metastaze/recidiv bolesti. Faktori koji su imali vrednost p < 0,2 posle izvršene univarijante analize (pol, dob, stadijum bolesti, raširena bolest (bulky disease), SUVmax, SUVmean, MTV, TLG), potom su obrađeni u multivarijantnom regresionom modelu. Posle multivarijantne regresione analize pol, TLG i raširena bolest prepoznati su kao statistički značajni faktori rizika za prognozu bolesti kod bolesnika sa IIHL. Zaključak. Prisustvo raširene bolesti u momentu postavljanja dijagnoze i visoka vrednost TLG kod određivanja primarnog stadijuma bolesti pomoću FDG-PET/CT su potencijalni faktori rizika i za DFS i OS kod bolesnika sa IIHL.

Ključne reči

Reference

Barton, M., Boyages, J., Crennan, E., Davis, S., Fisher, R.J., Hook, C., Johnson, N., Joseph, D., Khoo, V., Liew, K.H., Morgan, G., O`Brien, P., Pendlebury, S., Pratt, G., Quong, G., Roos, D.E., Thornton, D., Trotter, G., Walker, Q., Wallington, M. (1996) Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience. Radiotherapy and oncology, 39(1): 1-7
Ceriani, L., Martelli, M., Zinzani, P. L., Ferreri, A. J. M., Botto, B., Stelitano, C., Gotti, M., Cabras, M. G., Rigacci, L., Gargantini, L., Merli, F., Pinotti, G., Mannina, D., Luminari, S., Stathis, A., Russo, E., Cavalli, F., Giovanella, L., Johnson (2015) Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood, 126(8): 950-956
Córdoba, S. (2003) Early stage infradiaphragmatic Hodgkin's disease: results of radiotherapy and review of the literature. Radiotherapy and Oncology, 67(3): 259-263
Crnkovich, M.J., Leopold, K., Hoppe, R.T., Mauch, P.M. (1987) Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. Journal of Clinical Oncology, 5(7): 1041-1049
Cutuli, B., Petit, T., Hoffstetter, S., Velten, M., Dufour, P., Giron, C., Lederlin, P., Jung, G.M., Bergerat, J.P., Maloisel, F., Bey, P., Oberling, F. (1998) Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects. Oncology Reports
Darabi, K., Sieber, M., Chaitowitz, M., Braitman, L. E., Tester, W., Diehl, V. (2005) Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1114 patients. Leukemia & Lymphoma, 46(12): 1715-1720
Diehl, V. (2003) Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. Hematology, 2003(1): 225-247
Enrici, R.M., Osti, M.F., Anselmo, A.P., Banelli, E., Cartoni, C., Sbarbati, S., et al. (1996) Hodgkins disease stage I and II with exclusive subdiaphragmatic presentation: The experience of the Departments of Radiation Oncology and Hematology, University La Sapienza, of Rome. Tumori, 82(1): 48-52
Gallicchio, R., Mansueto, G., Simeon, V., Nardelli, A., Guariglia, R., Capacchione, D., Soscia, E., Pedicini, P., Gattozzi, D., Musto, P., Storto, G. (2014) F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. European Journal of Haematology, 92(5): 382-389
Hull, M.C., Price, M.N., Colgan, M.E. (2002) Subdiaphragmatic Hodgkin’s disease: The University of Florida experience. International Journal of Radiation Oncology*Biology*Physics, 52(1): 161-166
Iannitto, E., Accurso, V., Federico, M., Vallisa, D., Pieresca, C., Gravina, S.F., et al. (1997) Hodgkins disease presenting below the diaphragm: The experience of the Gruppo Italiano Studio Linfomi (GISL). Haematologica, 82(6): 676-682
Johnson, D.W., Hoppe, R.T., Cox, R.S., Rosenberg, S.A., Kaplan, H.S. (2006) Hodgkin's disease limited to intrathoracic sites. Cancer, 52(1): 8-13
Kälkner, K.M., Enblad, G., Gustavsson, A., Starkhammar, H., Branehög, I., Lenner, P., Glimelius, B. (2009) Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. European Journal of Haematology, 59(1): 31-37
Kim, T.M., Paeng, J.C., Chun, I.K., Keam, B., Jeon, Y.K., Lee, S., Kim, D., Lee, D.S., Kim, C.W., Chung, J., Kim, I.H., Heo, D.S. (2012) Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer, 119(6): 1195-1202
Liao, Z., Ha, C.S., Fuller, L.M., Hagemeister, F.B., Cabanillas, F., Tucker, S.L., Hess, M.A., Cox, J.D. (1998) Subdiaphragmatic stage I & II Hodgkin’s disease: long-term follow-up and prognostic factors. International Journal of Radiation Oncology*Biology*Physics, 41(5): 1047-1056
Mai, D.H., Peschel, R.E., Portlock, C., Knowlton, A., Farber, L. (1991) Stage I and II subdiaphragmatic Hodgkin's disease. Cancer, 68(7): 1476-1481
Mason, M., Law, M., Ashley, S., Nichols, J., Brada, M., Peckham, M., Horwich, A. (1992) Infradiaphragmatic Hodgkin's disease. European Journal of Cancer, 28(11): 1851-1852
Mauch, P., Greenberg, H., Lewin, A., Cassady, J. R., Weichselbaum, R., Hellman, S. (2007) Prognostic factors in patients with subdiaphragmatic Hodgkin's disease. Hematological Oncology, 1(3): 205-214
Partridge, S., Timothy, A., O`Doherty, M. J., Hain, S. F., Rankin, S., Mikhaeel, G. (2000) 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Annals of Oncology, 11(10): 1273-1279
Picardi, M., Soricelli, A., Grimaldi, F., Nicolai, E., Gallamini, A., Pane, F. (2011) Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Annals of oncology, 22(3): 671-80
Song, J.Y., Eberle, F.C., Xi, L., Raffeld, M., Rahma, O., Wilson, W.H., Dunleavy, K., Pittaluga, S., Jaffe, E.S. (2011) Coexisting and Clonally Identical Classic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma. American Journal of Surgical Pathology, 35(5): 767-772
Song, M., Chung, J., Lee, J., Jeong, S.Y., Lee, S., Hong, J., Chong, A., Moon, J., Kim, J., Lee, S., Kim, S.J., Shin, H. (2013) Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Science, 104(12): 1656-1661
Specht, L., Nissen, N.I. (1988) Hodgkins disease stages I and II with infradiaphragmatic presentation: A rare and prognostically unfavourable combination. Eur J Haematol, 40(5): 396-402
Swerdlow, A., Douglas, A., Vaughan, H.G., Vaughan, H.B., MacLennan, K. (1993) Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. British Journal of Cancer, 68(5): 1006-1011
Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 4th ed
Valette, F., Querellou, S., Oudoux, A., Carlier, T., Dupas, B., Chatal, J.-F., Couturier, O. (2007) Comparison of positron emission tomography and lymphangiography in the diagnosis of infradiaphragmatic hodgkin's disease. Acta Radiologica, 48(1): 59-63
Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., Konstantinou, N., Symeonidis, A., Karmiris, T., et al. (2006) Pure infradiaphragmatic Hodgkins lymphoma: Clinical features, prognostic factor and comparison with supradiaphragmatic disease. Haematologica, 91(1): 32-9